东宝生物(300239) - 2020 Q2 - 季度财报

Production Capacity and Expansion - The company has expanded its gelatin production capacity from 3,500 tons to 7,000 tons, with total annual gelatin capacity reaching 13,500 tons and collagen capacity at 3,000 tons[6]. - The company's construction of a 2,000-ton collagen production project has been completed, resulting in a 48.69% decrease in construction in progress compared to the beginning of the period[45]. - The annual production capacity for gelatin reached 13,500 tons, while collagen protein capacity was 3,000 tons following the launch of the fundraising project[61]. - The company is currently constructing several projects, including a 20,000-ton collagen protein peptide supplement production project, which is in the preparation stage[92]. - The company has committed to an investment project for the construction of a new gelatin production facility with an annual capacity of 3,500 tons, with a total investment of CNY 25,357 million, achieving 98.83% of the planned investment by the end of the reporting period[97]. Financial Performance - The company reported total operating revenue of ¥186,782,124.41, a decrease of 19.15% compared to the same period last year[26]. - Net profit attributable to shareholders was ¥6,779,047.92, down 61.70% year-on-year[26]. - The net profit after deducting non-recurring gains and losses was ¥3,844,553.20, a decline of 74.09% compared to the previous year[26]. - Basic earnings per share decreased to ¥0.0129, down 64.17% from the previous year[26]. - The weighted average return on net assets was 0.69%, a decrease of 1.35% compared to the previous year[26]. Market Strategy and Product Development - The company aims to strengthen its brand "Yuan Su Bone Peptide" in the senior market and has introduced new products such as "multi-flavor collagen peptide powder" and "fish collagen" to diversify its product line[8]. - The company is focusing on expanding into high-growth health markets, including nutrition and bone health, to capitalize on consumer trends[7]. - The company is enhancing its online marketing efforts, expanding into cross-border e-commerce and self-media channels to optimize its sales system[62]. - The company is focusing on market expansion in the fields of medicine, health, food, and beauty, aiming for diversified applications of collagen[60]. - The company has successfully developed new products, including a composite emulsifier and a new artificial meat project, indicating a diversification of collagen applications[51]. Challenges and Risks - The company has faced procurement risks due to increased costs from upstream suppliers and the ongoing impact of the pandemic, prompting it to strengthen its procurement strategies and explore new supply channels[11]. - The company faced challenges due to the COVID-19 pandemic, resulting in reduced demand from downstream customers and decreased international trade[40]. - Increased production costs were attributed to supply chain disruptions and higher procurement costs during the pandemic[41]. - The company emphasizes the importance of innovation and new product development to mitigate procurement price volatility risks[11]. Corporate Social Responsibility and Governance - The company has committed to corporate social responsibility by supporting pandemic relief efforts through donations and material support[13]. - The company emphasizes strict information disclosure and investor relations management, ensuring orderly operations under the new registration system[72]. - The company is committed to fulfilling its obligations regarding immediate return measures to protect investor interests[120]. - The company has made commitments to prevent any interference in its operational management by major shareholders[120]. Research and Development - The company has a strong focus on technological innovation, with 17 authorized patents, including 9 Chinese invention patents and 1 US invention patent[52]. - The company is committed to increasing R&D investment to support the industrialization and marketization of innovative projects[51]. - Research and development expenses were ¥6,415,004.61, down 41.99% from ¥11,058,175.06 in the previous year, due to the scheduling of R&D projects[74]. Environmental Compliance - The company has established an Environmental Protection Management Committee to oversee environmental compliance and pollution control measures[147]. - The company has not reported any major environmental incidents or exceedances of discharge limits during the reporting period[146]. - The company conducted annual emergency drills for environmental incidents to ensure preparedness and response capabilities[150]. Shareholder and Equity Management - The company did not distribute cash dividends or issue bonus shares during the reporting period[14]. - The company plans to continue its strategy of not distributing cash dividends or increasing share capital from capital reserves in the near term[114]. - The company has a three-year unlocking plan for equity incentive shares, with unlocking ratios of 40%, 30%, and 30%[162]. - The total number of ordinary shareholders at the end of the reporting period is 21,130[165].